Cargando…

Pilot clinical trials testing the safety and effects on the metastatic melanoma microenvironment of intratumoral interferon-gamma or imiquimod, plus a multipeptide melanoma vaccine

Detalles Bibliográficos
Autores principales:	Mauldin, Ileana S, Wages, Nolan A, Stowman, Anne M, Wang, Ena, Smolkin, Mark E, Olson, Walter C, Deacon, Donna H, Smith, Kelly T, Galeassi, Nadejda, Teague, Jessica E, Clark, Rachael A, Marincola, Francesco M, Petroni, Gina R, Mullins, David W, Slingluff, Craig L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4646116/ http://dx.doi.org/10.1186/2051-1426-3-S2-P139

Ejemplares similares

A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund’s adjuvant in melanoma patients
por: Melssen, Marit M., et al.
Publicado: (2019)

Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist
por: Meneveau, Max O, et al.
Publicado: (2021)

Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund’s adjuvant, cyclophosphamide, and polyICLC (Mel63)
por: Slingluff, Jr., Craig L, et al.
Publicado: (2021)

TLR2/6 agonists and IFNγ synergize to induce melanoma cells to produce T-cell recruiting chemokines
por: Mauldin, Ileana S, et al.
Publicado: (2013)

TLR2/6 agonists and IFN-gamma treatment induces favorable immune cell recruiting signatures from melanoma associated with STAT1 and IL-32 signaling
por: Mauldin, Ileana S, et al.
Publicado: (2014)

Heterogeneity in tertiary lymphoid structure B-cells correlates with patient survival in metastatic melanoma
por: Lynch, Kevin T, et al.
Publicado: (2021)

A multi-epitope melanoma helper peptide vaccine durably increases Th1 cytokine production by responding lymphocytes
por: Dillon, Patrick M, et al.
Publicado: (2013)

A melanoma helper peptide vaccine increases Th1 cytokine production by leukocytes in peripheral blood and immunized lymph nodes
por: Dillon, Patrick M, et al.
Publicado: (2014)

Tertiary lymphoid structures in desmoplastic melanoma have increased lymphocyte density, lymphocyte proliferation, and immune cross talk with tumor when compared to non-desmoplastic melanomas
por: Edmonds, Nicole L., et al.
Publicado: (2023)

Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk
por: Salerno, Elise P., et al.
Publicado: (2016)

Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund’s adjuvant (IFA) for resected high-risk melanoma
por: Patel, Sapna P, et al.
Publicado: (2021)

Defining the effects of age and gender on clinical immune response to cancer vaccination
por: Ramirez, Adriana, et al.
Publicado: (2014)

A randomized pilot trial evaluating safety and immunogenicity of recMAGE-A3 + AS15 immunotherapeutic administered by intramuscular versus intradermal/subcutaneous routes
por: Slingluff, Craig L, et al.
Publicado: (2014)

Immunologic hierarchy and promiscuity of melanoma helper peptides
por: Hu, Yinin, et al.
Publicado: (2013)

Melanoma Arising after Imiquimod Use
por: Paul, Sharad P.
Publicado: (2014)

Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma
por: Perales, Miguel-Angel, et al.
Publicado: (2008)

Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64)
por: Vavolizza, Rick D, et al.
Publicado: (2022)

Dynamic changes in cellular infiltrates with repeated cutaneous vaccination: a histologic and immunophenotypic analysis
por: Schaefer , Jochen T, et al.
Publicado: (2010)

A web tool for designing and conducting phase I trials using the continual reassessment method
por: Wages, Nolan A., et al.
Publicado: (2018)

Intratumoral IFN-γ or topical TLR7 agonist promotes infiltration of melanoma metastases by T lymphocytes expanded in the blood after cancer vaccine
por: Tran, Christine A, et al.
Publicado: (2023)

Intratumor and Intertumor Heterogeneity in Melanoma
por: Grzywa, Tomasz M., et al.
Publicado: (2017)

Immunomodulation by imiquimod in patients with high-risk primary melanoma
por: Narayan, Rupa, et al.
Publicado: (2011)

Imiquimod treatment of vulvar melanoma in situ invading the urethra
por: Fuchs, Esther, et al.
Publicado: (2021)

Characterization of a Multipeptide Lantibiotic Locus in Streptococcus pneumoniae
por: Maricic, Natalie, et al.
Publicado: (2016)

Intratumoral therapies and in-situ vaccination for melanoma
por: Huppert, Laura A., et al.
Publicado: (2022)

Regional vitiligo induced by imiquimod treatment for in-transit melanoma metastases
por: Tkachenko, Elizabeth, et al.
Publicado: (2019)

Management of lentiginous melanoma with imiquimod assessed by reflectance confocal microscopy
por: Han, Joseph, et al.
Publicado: (2023)

Immunoprevention of KRAS-driven lung adenocarcinoma by a multipeptide vaccine
por: Pan, Jing, et al.
Publicado: (2017)

Antibody response to melanoma helper-peptide vaccine correlates with survival
por: Olson, Walter C, et al.
Publicado: (2013)

Topical imiquimod in combination with brachytherapy for unresectable cutaneous melanoma scalp metastases
por: Yeh, Jennifer E., et al.
Publicado: (2022)

Melanoma-restricted genes
por: Wang, Ena, et al.
Publicado: (2004)

Topical Treatment of Melanoma In Situ, Lentigo Maligna, and Lentigo Maligna Melanoma with Imiquimod Cream: A Systematic Review of the Literature
por: Vaienti, Silvia, et al.
Publicado: (2023)

Using topical imiquimod for the management of positive in situ margins after melanoma resection
por: Pandit, Amrita S, et al.
Publicado: (2015)

Successful Treatment of Nivolumab-Resistant Multiple In-Transit Melanomas with Ipilimumab and Topical Imiquimod
por: Fujimura, Taku, et al.
Publicado: (2018)

Electrospun Poly(ε-caprolactone) Nanofibrous Mesh for Imiquimod Delivery in Melanoma Therapy
por: Lin, Wei-Chih, et al.
Publicado: (2018)

Malignant Melanoma Treated with Topical Imiquimod: A Bespoke Treatment That Spared the Amputation
por: Verga, Emanuele, et al.
Publicado: (2019)

Topical imiquimod and cryotherapy in combination with systemic immunotherapy in unresectable stage IIIC melanoma
por: Yeh, Jennifer E., et al.
Publicado: (2022)

Topically Applied Resiquimod versus Imiquimod as a Potential Adjuvant in Melanoma Treatment
por: Tambunlertchai, Supreeda, et al.
Publicado: (2022)

Intratumor Heterogeneity in Uveal Melanoma BAP-1 Expression
por: Stålhammar, Gustav, et al.
Publicado: (2021)

Intratumoral bacteria in uveal melanoma: A case report
por: Vega Escobar, Katherine, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5i8bts0464bfievdshjpsjq423